The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Temgesic 200 microgram Sublingual Tablets



Eumedica Pharmaceuticals GmbHPA23460/001/001

Main Information

Trade NameTemgesic 200 microgram Sublingual Tablets
Active SubstancesBuprenorphine hydrochloride
Dosage FormSublingual tablet
Licence HolderEumedica Pharmaceuticals GmbH
Licence NumberPA23460/001/001

Group Information

ATC CodeN02AE Oripavine derivatives
N02AE01 buprenorphine

Status

License statusAuthorised
Licence Issued01/02/2019
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceThis product contains a substance listed in Schedule 2 to the Misuse of Drugs Regulations 2017.
Marketing StatusNot marketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back